Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 12/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TXN | P10599 | 1/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22471169 | 0.82 | TAAR1 (0.44) | TAAR1HTR1AALOX15TXNTXNRD1 | |
| SCHEMBL22471008 | 0.80 | TBXAS1 (0.43) | TAAR1HTR1AALOX15TXNTXNRD1 | |
| SCHEMBL28547937 | 0.78 | TBXAS1 (0.45) | TAAR1HTR1AALOX15TXNTXNRD1 | |
| SCHEMBL12590300 | 0.77 | TAAR1 (0.45) | TAAR1HTR1AALOX15TXNTXNRD1 | |
| SCHEMBL27034035 | 0.76 | TAAR1 (0.41) | TAAR1HTR1AALOX15TXNTXNRD1 | |
| SCHEMBL7270060 | 0.74 | TAAR1 (0.42) | TAAR1HTR1AALOX15TXNTXNRD1 | |
| SCHEMBL585992 | 0.74 | — | — | |
| SCHEMBL11224676 | 0.73 | ALOX15 (0.48) | TAAR1HTR1AALOX15TERTALDH1A1 | |
| SCHEMBL25996725 | 0.73 | TAAR1 (0.46) | TAAR1HTR1AALOX15TXNTXNRD1 | |
| SCHEMBL8832585 | 0.73 | ALOX15 (0.38) | TAAR1HTR1AALOX15TERTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| WO-2018213777-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | KDM5A, KDM5B, KDM5C | TAAR1 4233/4885HTR1A 3240/4885ALOX15 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.